A2 consisting of botulinum toxin A, B, C, D, E, F and G.

19. The method of claim 17, further comprising treating the neurogenic inflammation by inhibiting at least one neurogenic inflammatory mediator selected from the group consisting of substance-P (SP), calcitonin gene-related peptide (cGRP), vasoactive intestinal peptide (VIP), interleukin-1 (IL-1), interleukin-2 (IL-2), nitric oxide (NO), 5-hydroxytryptamine (5-HT), tumor necrosis factor (TNF), and nerve growth factor (NGF).

20. The method of claim 17, wherein the botulinum toxin is less than about, or equal to 1000 U.

21. The method of claim 17, wherein the neurogenic inflammation is caused by rheumatoid arthritis.

22. The method of claim 17, wherein the neurogenic inflammation is caused by gout.

23. The method of claim 17, further comprising treating the neurogenic inflammation by inhibiting histamine.

REMARKS

Amendment to the Specification

Applicant has amended the specification to claim priority to U.S. Provisional Application Ser. No. 60/097,846, filed Aug. 25, 1998, and to incorporate that provisional application by reference in its entirety. Applicant notes that the declaration as originally filed referred to a claim of priority to U.S. Provisional Application Ser. No. 60/097,864, which was a typographical error, and was intended to refer to a claim of priority to U.S. Provisional Application Ser. No. 60/097,846.

Request to Declare Interference

Applicant hereby requests pursuant to 37 C.F.R. § 1.607 that an interference be